Fee-for-Service

Disparities in Access to Intravitreal Anti-VEGF Therapies Among Medicare Advantage Versus Fee-for-Service Beneficiaries

Medicare Advantage beneficiaries receive fewer higher-cost anti-VEGF injections compared to Fee-for-Service patients, highlighting potential access disparities to newer ophthalmic therapies.